Contact
Please use this form to send email to PR contact of this press release:
Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
TO:
Please use this form to send email to PR contact of this press release:
Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
TO: